Things They Are a Changing in the Field of Nontuberculous Mycobacteria
This issue of Clinics in Chest Medicine is dedicated to Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD). There has been an exponential increase in NTM-PD in many regions of the world over the past 20 years. The last review on Nontuberculous Mycobacteria in Clinics in Chest Medicine was published in 2015. Since that issue, we have witnessed a historical milestone in the field of NTM-PD. The first drug was approved by the FDA for the treatment of refractory Mycobacterium avium complex (MAC) pulmonary disease. (Source: Clinics in Chest Medicine)
Source: Clinics in Chest Medicine - October 26, 2023 Category: Respiratory Medicine Authors: Shannon Kasperbauer, Rachel Thomson Tags: Preface Source Type: research
Nontuberculous Mycobacterial Pulmonary Disease
CLINICS IN CHEST MEDICINE (Source: Clinics in Chest Medicine)
Source: Clinics in Chest Medicine - October 26, 2023 Category: Respiratory Medicine Authors: Shannon Kasperbauer, Rachel Thomson Source Type: research
Copyright
ELSEVIER (Source: Clinics in Chest Medicine)
Source: Clinics in Chest Medicine - October 26, 2023 Category: Respiratory Medicine Source Type: research
Contributors
SHANNON KASPERBAUER, MD (Source: Clinics in Chest Medicine)
Source: Clinics in Chest Medicine - October 26, 2023 Category: Respiratory Medicine Source Type: research
Contents
Shannon Kasperbauer and Rachel Thomson (Source: Clinics in Chest Medicine)
Source: Clinics in Chest Medicine - October 26, 2023 Category: Respiratory Medicine Source Type: research
Forthcoming Issues
Sarcoidosis (Source: Clinics in Chest Medicine)
Source: Clinics in Chest Medicine - October 26, 2023 Category: Respiratory Medicine Source Type: research
Biomarkers in Sarcoidosis
At present, no biomarker exists which is truly specific for sarcoidosis and the ones available have modest sensitivity and specificity. The clinical context should dictate the choice of biomarker(s) used to address different clinical questions such as diagnosis, monitoring disease activity or monitoring response to treatment. In the future, in addition to known serum biomarkers, it seems fruitful to further explore a possible role of imaging, exhaled air and even biopsy-related biomarkers in sarcoidosis to guide clinical management. (Source: Clinics in Chest Medicine)
Source: Clinics in Chest Medicine - October 11, 2023 Category: Respiratory Medicine Authors: Sophie C. van der Mark, Vikaash W.S. Bajnath, Marcel Veltkamp Source Type: research
Global Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease
Nontuberculous mycobacterial (NTM) isolation and pulmonary disease (NTM-PD) have continued to increase in most regions of the world, driven mainly by Mycobacterium avium. Single-center studies also support increasing trends as well as a persistent burden of undiagnosed NTM among persons suspected of having tuberculosis (TB), in countries with moderate-to-high TB prevalence. Cumulative exposure to water and soil presents an increased risk to susceptible hosts, and trace metals in water supply are recently recognized risk factors. Establishing standard case definitions for subnational and national surveillance systems with m...
Source: Clinics in Chest Medicine - September 21, 2023 Category: Respiratory Medicine Authors: D. Rebecca Prevots, Julia E. Marshall, Dirk Wagner, Kozo Morimoto Source Type: research
Imaging of Solid Pulmonary Nodules
Early detection with accurate classification of solid pulmonary nodules is critical in reducing lung cancer morbidity and mortality. Computed tomography (CT) remains the most widely used imaging examination for pulmonary nodule evaluation; however, other imaging modalities, such as PET/CT and MRI, are increasingly used for nodule characterization. Current advances in solid nodule imaging are largely due to developments in machine learning, including automated nodule segmentation and computer-aided detection. This review explores current multi-modality solid pulmonary nodule detection and characterization with discussion of...
Source: Clinics in Chest Medicine - September 19, 2023 Category: Respiratory Medicine Authors: Claire F. Woodworth, Livia Maria Frota Lima, Brian J. Bartholmai, Chi Wan Koo Source Type: research
Smoking-Related Interstitial Lung Disease and Emphysema
Diagnosis and treatment of patients with smoking-related lung diseases often requires multidisciplinary contributions to optimize care. Imaging plays a key role in characterizing the underlying disease, quantifying its severity, identifying potential complications, and directing management. The primary goal of this article is to provide an overview of the imaging findings and distinguishing features of smoking-related lung diseases, specifically, emphysema/chronic obstructive pulmonary disease, respiratory bronchiolitis –interstitial lung disease, smoking-related interstitial fibrosis, desquamative interstitial pneumonit...
Source: Clinics in Chest Medicine - September 15, 2023 Category: Respiratory Medicine Authors: Joanna G. Escalon, Francis Girvin Source Type: research
Interpreting Lung Cancer Screening CTs
Lung cancer screening via low-dose computed tomography (CT) reduces mortality from lung cancer, and eligibility criteria have recently been expanded to include patients aged 50 to 80 with at least 20 pack-years of smoking history. Lung cancer screening CTs should be interepreted with use of Lung Imaging Reporting and Data System (Lung-RADS), a reporting guideline system that accounts for nodule size, density, and growth. The revised version of Lung-RADS includes several important changes, such as expansion of the definition of juxtapleural nodules, discussion of atypical pulmonary cysts, and stepped management for suspicio...
Source: Clinics in Chest Medicine - September 14, 2023 Category: Respiratory Medicine Authors: Khushboo Jhala, Suzanne C. Byrne, Mark M. Hammer Source Type: research
Update on Interstitial Pneumonias
This article reviews the recent 2022 IPF clinical practice guideline with a focus on the imaging updates. (Source: Clinics in Chest Medicine)
Source: Clinics in Chest Medicine - September 14, 2023 Category: Respiratory Medicine Authors: Melissa B. Carroll, Jeffrey P. Kanne, Maria Daniela Martin Rother Source Type: research
Anti-inflammatory Therapy for Sarcoidosis
Over 50% of patients with sarcoidosis will require anti-inflammatory therapy at some point in their disease course. Indications for therapy are to improve health-related quality of life, prevent or arrest organ dysfunction (or organ failure) or avoid death. Recently published treatment guidelines recommended a stepwise approach to therapy however there are some patients for whom up front combination or more intense therapy maybe reasonable. The last decade has seen an explosion of studies and trials evaluating novel therapeutic agents and treatment strategies. Currently available anti-inflammatory therapies and several nov...
Source: Clinics in Chest Medicine - September 6, 2023 Category: Respiratory Medicine Authors: Ogugua Ndili Obi Source Type: research
Neurosarcoidosis and Neurologic Complications of Sarcoidosis Treatment
Sarcoidosis is an immune-mediated multisystem granulomatous disorder. Neurosarcoidosis (NS) accounts for 5% to 35% of cases. The diagnostic evaluation of NS can be a clinical challenge. Gadolinium-enhanced magnetic resonance imaging (MRI) is the gold standard to evaluate central nervous system NS. In almost all cases treatment is warranted. Although glucocorticoids remain the first-line therapy in patients with sarcoidosis, in NS timely initiation of second- or third-line treatment is strongly recommended. Of these, tumor necrosis factor-alpha inhibitors are the most promising. However, the treatment itself may be responsi...
Source: Clinics in Chest Medicine - September 4, 2023 Category: Respiratory Medicine Authors: Mareye Voortman, Marjolein Drent, Barney J. Stern Source Type: research
Cardiac Sarcoidosis
Cardiac involvement is a major cause of morbidity and mortality in patients with sarcoidosis. It is important to distinguish between clinical manifest diseases from clinically silent diseases. Advanced cardiac imaging studies are crucial in the diagnostic pathway. In suspected isolated cardiac sarcoidosis, it ’s key to rule out alternative diagnoses. Therapeutic options can be divided into immunosuppressive agents, guideline-directed medical therapy, antiarrhythmic medications, device/ablation therapy, and heart transplantation. (Source: Clinics in Chest Medicine)
Source: Clinics in Chest Medicine - September 4, 2023 Category: Respiratory Medicine Authors: Manuel L. Ribeiro Neto, Christine L. Jellis, Paul C. Cremer, Logan J. Harper, Ziad Taimeh, Daniel A. Culver Source Type: research
